Company · ATTO
Attovia Therapeutics, Inc.
Nasdaq's symbol directory lists ATTO on Nasdaq as “Attovia Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders bought on 6 occasions ($42.1M); insiders sold on 1 occasion ($2.3M); 4 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- GOLDMAN SACHS GROUP INC sold $2.3M · bought $10.3M
- Redmile Group, LLC bought $10.2M
- Frazier Life Sciences XI, L.P. bought $10.0M
- venBio Global Strategic Fund IV, L.P. bought $6.5M
- Sanofi bought $5.1M
Every trade (7)
- BUYRedmile Group, LLC bought $10.2M
- BUYFrazier Life Sciences XI, L.P. bought $10.0M
- BUYGOLDMAN SACHS GROUP INC bought $8.5M
- BUYvenBio Global Strategic Fund IV, L.P. bought $6.5M
- BUYSanofi bought $5.1M
- SELLGOLDMAN SACHS GROUP INC sold $2.3M
- BUYGOLDMAN SACHS GROUP INC bought $1.8M
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Alamar HoldCo, LLC 7.1%
- GOLDMAN SACHS GROUP INC 6.7%
- Deep Track Capital, LP 7.45%
- Frazier Life Sciences Public Fund, L.P. 1.7%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition; Other events Nov 9, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.